A team led by researchers from Mass General Brigham reports promising results for a monoclonal antibody that takes aim at a new target for Alzheimer’s disease.
Agilent agrees to acquire BIOVECTRA for $925m
A BIOVECTRA manufacturing facility. Credit: Agilent Technologies, Inc. / Business Wire. Agilent Technologies has announced a definitive agreement for the acquisition of Canadian contract development